Rigel Pharmaceuticals, Inc. logo RIGL - Rigel Pharmaceuticals, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 8
HOLD 7
SELL 0
STRONG
SELL 0
| PRICE TARGET: $27.33 DETAILS
HIGH: $42.00
LOW: $2.00
MEDIAN: $38.00
CONSENSUS: $27.33
DOWNSIDE: 5.31%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 85% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Undervalued Strong
Trading 56.0% below fair value
Current Price $28.86
Bear Case $50.99 76.7% upside ($50.99 - $28.86) / $28.86 = 76.7% 6% stage 1 growth, 11% discount
Fair Value $65.59 127.3% upside ($65.59 - $28.86) / $28.86 = 127.3% 9% stage 1 growth, 11% discount
Bull Case $79.64 175.9% upside ($79.64 - $28.86) / $28.86 = 175.9% 12% stage 1 growth, 11% discount

Adjust Assumptions

9.2%
11.0%
3.0%

Key Value Driver

FCF growth rate (9% base case)

Terminal Value % of EV 38%
Implied Market Multiple 6.5x

Plain-Language Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $27.33 from 15 analysts, using a 25% weight on analyst consensus. That produces an estimated intrinsic value of $65.59 per share.

Warnings

ℹ Wall Street's average price target is $27.33 (from 15 analysts). Our estimate is 187% above the consensus -- consider that gap carefully.

Key Risks

  • P/E alone misleads — earnings depressed by growth investment
  • Cyclical or commodity businesses may be misclassified as platforms
  • Terminal value dominance suggests sensitivity to long-run assumptions